L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome

HIV Med. 2001 Jan;2(1):59-60. doi: 10.1046/j.1468-1293.2001.00049.x.

Abstract

The objective of this pilot study was to assess the effect of L-carnitine on the course of the HIV-associated lipodystrophy syndrome. Twelve patients presenting with combined atrophic and hypertrophic changes of body fat were treated with L-carnitine 1000 mg bid for 3 months. No marked improvement of the body changes was observed. However a reduction in serum cholesterol levels, but not triglycerides, was noted. These preliminary data do not support the use of L-carnitine for the rapid reversal of advanced fat tissue alterations due to HIV-associated lipodystrophy.

MeSH terms

  • Body Weight
  • Carnitine / therapeutic use*
  • Cholesterol, LDL
  • HIV Wasting Syndrome / drug therapy*
  • Humans
  • Lipodystrophy / drug therapy*
  • Pain Measurement
  • Pilot Projects

Substances

  • Cholesterol, LDL
  • Carnitine